I have been thinking about B-OM and the fact that we have not really heard anything about the start of a P-III clinical trial considering the end of P-II meetings with the FDA (Nov 2018) and EMA took place quite a while ago. With the up front payment from Alfasigma, it would seem IPIX would be anxious to get going on the trials for B-OM. I wonder why they have been so quiet...….??